UniXell
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $28M
Overview
A Chinese biotech developing autologous iPSC-derived cell therapies for neurodegenerative diseases like Parkinson's.
NeurologyRare Diseases
Technology Platform
Integrated platform for autologous iPSC therapy, featuring proprietary reprogramming, directed differentiation, SISBAR single-cell lineage tracing for safety, and high-precision gene editing.
Opportunities
First-mover advantage in China's autologous iPSC therapy space for Parkinson's disease; successful clinical data for UX-DA001 could validate the platform for broader CNS and rare disease applications and attract global partnerships.
Risk Factors
High clinical and regulatory risk associated with novel, complex autologous iPSC therapies; significant manufacturing complexity and cost scalability challenges; competition from allogeneic cell therapy approaches and other neuromodulatory therapies.
Competitive Landscape
Competes with other cell therapy developers for Parkinson's like BlueRock Therapeutics (allogeneic, acquired by Bayer) and Aspen Neuroscience (autologous), but holds a distinct first-in-China position for autologous iPSC-derived dopaminergic neuron therapy.